Endotoxin, a lipopolysaccharide (LPS), is a type of pyrogen and is a component of the exterior cell wall of gram-negative bacteria. To ensure the safety of a patient, endotoxin content in the drug should always be controlled. In biological processing, it may emanate from facility, utility, raw materials, process, and personnel.
In this webinar, you will learn:
Somasundaram G (Som)
Som is a consultant with customers for regulatory compliance, closed processing, and other areas in biopharmaceutical applications. He is also a member of PDA and ISPE industry associations. Som has worked in different functions within Merck for the last 19 years, including heading technology management, tech service, BioReliance® filter validation lab, commercial role, and business development areas. He also worked for a year in QA/QC as well as obtained one year of academic experience in microbiology.
Subhasis Banerjee, Ph.D.
Principal Bioprocessing Application Expert
Subhasis supports the technical consultation for downstream processing for the APAC region. He has a Ph.D. in biochemistry with post-doctoral experience from The Ohio State University, Columbus, USA. He has contributed to several publications in international peer-reviewed journals and conducted presentations in numerous national and international Conferences.